Elevance Health Beats Q1 Earnings, Raises 2026 Guidance Despite CMS Charge
Elevance Health (ELV) delivered stronger-than-expected first quarter results, reporting earnings of $8.00 per share that exceeded analyst expectations despite a significant regulatory charge. The health insurer raised its full-year guidance, signaling confidence in its underlying business momentum even as membership continues to decline in key segments.
Key Numbers
The Indianapolis-based insurer reported first quarter diluted earnings per share of $8.00, with adjusted EPS reaching $12.58 when excluding one-time items. The adjusted figure benefited from approximately $1 per share in non-recurring investment income, helping offset a $935 million accrual related to a Centers for Medicare & Medicaid Services (CMS) matter.
Operating revenue increased 1.5% year-over-year to $49.5 billion, driven by higher premium yields in the Health Benefits segment and growth in CarelonRx product revenue. However, this modest top-line growth came despite anticipated membership declines across Medicare Advantage, Medicaid, and Employer Group risk products.
The company's benefit expense ratio rose 40 basis points to 86.8%, reflecting elevated medical costs in its Medicaid business, though this was partially offset by improved performance in Medicare. Operating margin compressed to 4.2% from 6.5% in the prior year, primarily due to the CMS accrual and a $129 million business optimization charge.
Medical membership stood at 45.4 million as of March 31, 2026, representing a slight increase of 186,000 members from year-end 2025. However, this masks significant shifts in the membership mix, with commercial fee-based membership growth offsetting strategic exits from less profitable Medicare Advantage and Employer Group risk segments.
Operating cash flow surged to $4.3 billion in the quarter, up $3.3 billion year-over-year, reflecting underlying business strength and favorable working capital dynamics. The company maintained a strong balance sheet with $2.2 billion in cash and investments at the parent company level.
What Management Said
CEO Gail Boudreaux struck an optimistic tone despite the mixed results, stating that "first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience." She emphasized that the company's actions are "driving more consistent performance" and positioning Elevance Health for "continued improvement over time."
Management's confidence was reflected in the raised full-year guidance. The company now expects 2026 adjusted diluted EPS of at least $26.75, up from previous guidance, citing "underlying business strength, actions to reduce medical costs, and increased visibility" into the remainder of the year.
The company acknowledged the CMS matter's impact but included it in their full-year diluted EPS guidance of at least $19.85, suggesting management views this as a manageable one-time issue rather than an ongoing concern. The reaffirmation of operating cash flow guidance at $5.5 billion, inclusive of potential CMS-related cash payments, further reinforces this view.
Regarding the membership shifts, management characterized the declines in Medicare Advantage and Employer Group risk as "disciplined action to reposition these businesses for sustainable performance," indicating a strategic focus on profitability over volume.
What to Watch
Several key factors will determine Elevance's trajectory through 2026. First, the company's ability to manage medical cost trends, particularly in its challenged Medicaid business, will be critical. The 40 basis point increase in the benefit expense ratio suggests ongoing pressure that needs to be addressed.
The strategic membership repositioning bears close monitoring. While management frames the Medicare Advantage membership decline of 15.8% year-over-year as deliberate, investors will want to see evidence that remaining members are indeed more profitable and that the company can stabilize these books of business.
The Carelon segment's performance presents both opportunity and concern. While revenue grew 7.9% to $18 billion, operating margin compressed from 6.6% to 5.9% as the company continues investing in risk-based capabilities. The success of these investments in driving future growth will be crucial for justifying the current margin pressure.
Capital deployment remains a bright spot, with the company returning $1.5 billion to shareholders through $1.1 billion in share buybacks and $376 million in dividends during the quarter. With $5.6 billion remaining in share repurchase authorization and strong cash generation, continued shareholder returns appear sustainable.
Finally, resolution of the CMS matter and its ultimate financial impact warrants attention. While management has accrued $935 million and incorporated this into guidance, any deviation from this estimate could impact full-year results.
The raised guidance suggests management sees clear paths to improved performance, but execution on medical cost management and successful navigation of the membership mix shift will determine whether Elevance can deliver on these elevated expectations.
Byline: StockCliff Research